bioMérieux S.A.
bioMérieux S.A. Fundamental Analysis
bioMérieux S.A. (BMXMF) shows weak financial fundamentals with a PE ratio of 26.32, profit margin of 9.76%, and ROE of 9.89%. The company generates $4.1B in annual revenue with weak year-over-year growth of 2.26%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 54.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze BMXMF's fundamental strength across five key dimensions:
Efficiency Score
WeakBMXMF struggles to generate sufficient returns from assets.
Valuation Score
WeakBMXMF trades at a premium to fair value.
Growth Score
WeakBMXMF faces weak or negative growth trends.
Financial Health Score
ExcellentBMXMF maintains a strong and stable balance sheet.
Profitability Score
WeakBMXMF struggles to sustain strong margins.
Key Financial Metrics
Is BMXMF Expensive or Cheap?
P/E Ratio
BMXMF trades at 26.32 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, BMXMF's PEG of 5.71 indicates potential overvaluation.
Price to Book
The market values bioMérieux S.A. at 2.55 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 11.12 times EBITDA. This signals the market has high growth expectations.
How Well Does BMXMF Make Money?
Net Profit Margin
For every $100 in sales, bioMérieux S.A. keeps $9.76 as profit after all expenses.
Operating Margin
Core operations generate 9.54 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.89 in profit for every $100 of shareholder equity.
ROA
bioMérieux S.A. generates $7.13 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
bioMérieux S.A. produces operating cash flow of $789.56M, showing steady but balanced cash generation.
Free Cash Flow
bioMérieux S.A. generates strong free cash flow of $453.72M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $3.85 in free cash annually.
FCF Yield
BMXMF converts 4.32% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
26.32
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
5.71
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.55
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.57
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.11
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.39
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How BMXMF Stacks Against Its Sector Peers
| Metric | BMXMF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 26.32 | 28.45 | Neutral |
| ROE | 9.89% | 763.00% | Weak |
| Net Margin | 9.76% | -45265.00% (disorted) | Weak |
| Debt/Equity | 0.11 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 2.39 | 2795.60 | Strong Liquidity |
| ROA | 7.13% | -16588.00% (disorted) | Weak |
BMXMF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews bioMérieux S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
30.73%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-1.54%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
35.48%
Industry Style: Defensive, Growth, Innovation
High Growth